ABCSG Trial: Survival Benefit for Tamoxifen → Anastrozole

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

ABCSG Trial: Survival Benefit for Tamoxifen. Anastrozole Updated results from Austrian Breast and Colorectal Cancer Study Group Trial 8 confirmed a survival difference for the sequencing strategy of tamoxifen followed by anastrozole (Arimidex), compared to 5 years of tamoxifen (abstract 14). Preliminary results (median follow-up 55 mo) had previously revealed a 24% reduction in recurrence in favor of the sequencing strategy, although the difference was not statistically significant.

ABCSG Trial: Survival Benefit for Tamoxifen → Anastrozole Updated results from Austrian Breast and Colorectal Cancer Study Group Trial 8 confirmed a survival difference for the sequencing strategy of tamoxifen followed by anastrozole (Arimidex), compared to 5 years of tamoxifen (abstract 14). Preliminary results (median follow-up 55 mo) had previously revealed a 24% reduction in recurrence in favor of the sequencing strategy, although the difference was not statistically significant.

Raimund Jakesz, MD, presented mature results of Trial 8, involving 3,714 postmenopausal women with newly diagnosed hormone-sensitive early breast cancer. At a median follow-up of 72 months, a sequencing strategy of 2 years of tamoxifen followed by 3 years of anastrozole improved recurrence-free survival (RFS) vs 5 years of tamoxifen. With the sequencing approach, RFS events were reduced by 21% (P = .038) regardless of whether patients actually received the assigned treatment, and by 27% (P = .001) in patients who received treatment as planned.

Patients with sequential endocrine treatment also had a significant improvement in overall survival (see figure). In the intent-to-treat analysis of all patients, deaths were significantly reduced by 22% (P = .032). Higher levels of estrogen receptor or progesterone receptor positivity were predictive of longer RFS and overall survival, the risks of which were reduced by approximately 35% with sequencing, Dr. Jakesz reported.

“Switching from tamoxifen to anastrozole after 2 years of tamoxifen significantly improves recurrence-free and overall survival,” he concluded. “This trial clearly shows a survival benefit over 5 years of adjuvant tamoxifen.”
 

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.
1 expert is featured in this series.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
Related Content